Bora Pharmaceuticals: 2Q26 Results: In-line earnings recovery with CDMO expansion on track
Institutional-grade analysis used by equity desks before repricing events. 11 pages.
Report fact snapshot
- Publisher
- JPMorgan
- Date
- 2026-08-18
- Type
- Company Report
- Region
- Greater China, United States, Asia Pacific
- Sector
- Healthcare & Biotech
- Companies
- Target, 3M, Results, Bora
- Key signal
- 1m
Market is pricing this as noise.
Data shows a structural shift is underway.
Sector models are broken — re-rating is imminent.
Based on JPMorgan research, August 2026 data and regional breakdowns
Key Research Signals
Market is pricing this as noise.
Data shows a structural shift is underway.
Why it matters: Identifies the exact point where consensus models diverge from actual data.
A re-rating catalyst is approaching.
Consensus has not yet reflected this shift.
Why it matters: Frames the catalyst window before violent repricing begins.
Winners are concentrated in this space.
Specific companies are structurally outperforming.
Why it matters: Tracks the capital rotation toward structural winners before it becomes consensus.
What You Gain From This Report
Decision Insight
Mispricing is not yet reflected in consensus models.
Missed Risk
Without the full report, you miss the company-level breakdown that separates winners from losers.
Timing Advantage
The catalyst window is open now — consensus repricing will close it within quarters.
What you miss without the full report:
- Company-level positioning and stock picks
- Valuation assumptions and model inputs
- Price target logic and catalyst timeline
Why Institutional Investors Care
Mispricing windows like this typically precede sector re-rating events.
Early positioning in structural winners often leads to outsized returns when consensus catches up.
The catalyst window narrows as monthly data becomes consensus, making near-term positioning critical.
Report Summary
We believe Bora Pharmaceuticals has moved past its most challenging period. The tariff-related order delays and US integration costs that weighed on 2025 performance are now abating, positioning 2026 as a potential inflection year. The completion of the MacroGenics facility acquisition, an expanding portfolio of commercial and R&D partnerships, and early conversion of Top-20 pharma pipeline opportunities into signed contracts underpin our constructive outlook. We expect utilization, backlog, and deal flow to improve progressively YTD 1m 3m 12m from here. President Trump’s proposed tariffs on imported Abs -17.1% 2.2% 4.2% -48.0% generics, if executed, could also support the longer-term growth Our Dec-27 PT of NT$540 is based on a DCF valuation that 52-week range (NT$) 795.00-330.50
Institutional Content Below
Full PDF (11 pages), valuation models, broker logic, and detailed charts.
Key Takeaways
- 2Q26 earnings recap pointed to a clear recovery, with the newly emerged Style Exposure
- 2% in 2Q26; the CDMO backlog also reached a record US$317 million due
- CDMO remains the core growth engine, with more contracts and more
- CHC is not a core business, but it is now consolidated because of the higher
- The Taiwan plant sale and US plant purchases reflect a network optimization
- Model update: We have increased our sales forecasts by 2-5% for 26E-28E given
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the JPMorgan Bora Pharmaceuticals report. It helps users review Bora Pharmaceuticals: 2Q26 Results: In-line earnings recovery with CDMO expansion on track coverage, key takeaways, and related broker or sector research paths across pharma, consumer, earnings; Target, 3M.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.
Request Full PDF Access
Get access to the full broker report, including company-level details, valuation assumptions, charts, and price target logic.
Access is provided through VIP service or request confirmation.